BBIO Stock Forecast & Price Target

BridgeBio Pharma is in a strong position, with increased clarity on the competitive outlook and a durable growth forecasted through mid-2031. The recent settlement with competitors on their ATTR-CM drug, tafamidis, extends their loss of exclusivity to 2031, giving BridgeBio an upside scenario for its key program, Attruby. The company's valuation, which solely ascribes value to a few key programs, yields an enterprise value of ~$21.3B and a price objective of $100 per share. Risks to achieving this price include negative clinical data, delays in approvals, and difficulties establishing a productive commercial infrastructure. However, the recent patent settlement may extend Acoramidis's exclusivity into the late 2030s, providing additional upside potential for the company.

BridgeBio Pharma is currently facing multiple key milestones in their pipeline, with their lead drug Attruby showing positive results and strong KOL feedback. The company also has three potential drug launches by the end of the year, with infigratinib expected to enter the European market by the end of 2027. Furthermore, their recent settlements with generic drug manufacturers will push the earliest introduction of generic tafamidis to mid-2031, which could potentially stabilize revenues for the company. However, the company's reliance on their key programs and the uncertainty surrounding their timeline for FDA approval raises concerns about the sustainability of their revenue and the overall financial health of the company in the long term.